(Q52895479)

English

Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.

scientific article published on 15 December 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

B-cell lymphoma

1 reference

based on heuristic

inferred from title

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Annalisa Chiappella

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Roberto Marasca

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Pellegrino Musto

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

M Christina Cox

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

7

object named as

Monica Tani

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Renato Zambello

10

object named as

Renato Zambello

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Maria Giuseppina Cabras

9

object named as

Maria Giuseppina Cabras

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Annalisa Arcari

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Luca Zanlari

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Patrizia Bernuzzi

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Vanessa Valenti

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Alberto Santagostino

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Fiorella Ilariucci

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Giuseppe Carli

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Paolo Savini

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Dario Marino

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Francesco Ghio

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Massimo Gentile

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Daniele Vallisa

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

15 December 2015

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Leukemia & Lymphoma

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

57

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1823-1830

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

The epidemiology of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Relapsed/refractory diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Bendamustine: rebirth of an old drug

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL).

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Identifiers

10.3109/10428194.2015.1106536

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52895479&oldid=1858457880"